Chapter 1.     NON-ALCOHOLIC STEATOHEPATITIS MARKET   – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2.     NON-ALCOHOLIC STEATOHEPATITIS MARKET    – Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

 2.3.1. Impact during 2023 - 2030

  2.3.2. Impact on Supply – Demand

Chapter 3.     NON-ALCOHOLIC STEATOHEPATITIS MARKET    – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4.     NON-ALCOHOLIC STEATOHEPATITIS MARKET  - Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5.     NON-ALCOHOLIC STEATOHEPATITIS MARKET   - Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6.  NON-ALCOHOLIC STEATOHEPATITIS MARKET – By  Drug Type

6.1. Vitamin E and Pioglitazone

6.2. Obeticholic Acid (OCA)

6.3. Lanifibranor

6.4. Semaglutide

6.5. Resmetirom

6.6. Aramchol

6.7. Cenicriviroc

6.8. Others

Chapter 7.    NON-ALCOHOLIC STEATOHEPATITIS MARKET      – By End Use

7.1. Hospital Pharmacies

7.2. Retail & Specialty Pharmacies

7.3. Others

Chapter 8.    NON-ALCOHOLIC STEATOHEPATITIS MARKET    – By Region